Related Experiment Videos
Improving the efficacy of BCG immunotherapy by dose reduction
1Istituto di Urologia, Universitá degli Studi, Monoblocco Ospedaliero, Padova, Italia.
European Urology
|January 1, 1995
Summary
Low-dose intravesical bacillus Calmette-Guérin (BCG) therapy shows better response rates and fewer side effects for superficial bladder cancer compared to standard-dose BCG. This finding supports optimizing BCG treatment regimens for improved patient outcomes.
Area of Science:
- Urology
- Oncology
- Immunotherapy
Background:
- Intravesical bacillus Calmette-Guérin (BCG) is established for superficial bladder cancer treatment.
- Optimal BCG dosage for efficacy and reduced toxicity remains undefined.
- Previous studies suggest low-dose BCG may offer a favorable balance of response and side effects.
Purpose of the Study:
- To compare the efficacy and toxicity of low-dose versus standard-dose intravesical BCG for superficial bladder cancer.
- To clarify the relationship between BCG dose, treatment response, and adverse events.
- To evaluate BCG efficacy across different stages of non-muscle invasive bladder cancer.
Main Methods:
- Phase III randomized trial comparing low-dose (75 mg) and standard-dose (150 mg) BCG (Pasteur strain).
- Interim analysis of 183 patients assessing tumor recurrence and progression.
- Evaluation of treatment response and side effects including cystitis, fever, and hematuria.
- Analysis of outcomes stratified by tumor stage (TaM, T1M, CIS).
Main Results:
- Low-dose BCG demonstrated significantly higher response rates (p = 0.0009).
- Common side effects like cystitis, fever, and hematuria were significantly reduced with low-dose BCG (p < 0.05).
- In T1M and CIS stages, low-dose BCG showed superior tumor-free rates (82% and 64% vs. 0% for standard-dose). No difference was observed in TaM stage.
- An additional course of BCG improved response in non-responders for both dose groups.
- No significant difference in progression rates was observed between the groups.
Conclusions:
- Low-dose intravesical BCG (75 mg) is effective and better tolerated than standard-dose (150 mg) for superficial bladder cancer, particularly for T1M and CIS stages.
- The findings support the use of a reduced BCG dose to improve patient compliance and reduce toxicity without compromising efficacy in certain patient groups.
- Further investigation into optimized BCG dosing strategies is warranted to maximize therapeutic benefit in bladder cancer management.